세계의 유모세포 백혈병 시장 : 규모 - 치료 유형별, 치료법별, 제품 유형별, 약물 유형별, 투여 경로별, 최종 사용자별, 지역별 전망, 경쟁 전략, 부문별 전망(-2033년)

Hairy Cell Leukemia Market Size- By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

US $ 4,250 ￦ 6,149,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인용 시에는 출처를 명시해 주시기 바랍니다

US $ 5,650 ￦ 8,174,000

PDF (Group License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

US $ 7,450 ￦ 10,779,000

PDF (Company License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

한글목차

세계의 유모세포 백혈병 시장 규모는 향후 4.89%의 CAGR로 확대되어 2033년까지 1억 달러에 달할 것으로 예상됩니다.

이 보고서는 세계의 유모세포 백혈병(Hairy Cell Leukemia) 시장을 조사했으며, 시장 개요와 함께 치료 유형별/치료법별/제품 유형별/약물 유형별/투여 경로별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

• 성장 촉진요인, 억제요인, 기회, 과제 분석
• COVID-19의 세계 유모세포 백혈병 시장에 대한 영향

제5장 시장 변수와 전망

• SWOT 분석
• PESTEL 분석
• Porter's Five Forces
• 히트맵 분석

제6장 경쟁 구도

제7장 세계의 유모세포 백혈병 시장, 치료 유형별(100만 달러)

• 세계의 유모세포 백혈병 시장 매출 점유율과 예측, 치료 유형별, 2023년-2033년
• 투약 치료
• 외과 수술

제8장 세계의 유모세포 백혈병 시장, 치료법별(100만 달러)

• 세계의 유모세포 백혈병 시장 매출 점유율과 예측, 치료법별, 2023년-2033년
• 화학요법
• 면역치료
• 표적치료

제9장 세계의 유모세포 백혈병 시장, 제품 유형별(100만 달러)

• 세계의 유모세포 백혈병 시장 매출 점유율과 예측, 제품 유형별, 2023년-2033년
• 캡슐
• 비경구약
• 태블릿
• 기타

제10장 세계의 유모세포 백혈병 시장, 약제 클래스별(100만 달러)

• 세계의 유모세포 백혈병 시장 매출 점유율과 예측, 약제 클래스별, 2023년-2033년
• Belzutifan
• Bevacizumab
• Carmustine
• Everolimus
• Lomustine
• Temozolomide
• 기타

제11장 세계의 유모세포 백혈병 시장, 투여 경로별(100만 달러)

• 세계의 유모세포 백혈병 시장 매출 점유율과 예측, 투여 경로별, 2023년-2033년
• 경구
• 비경구
• 기타

제12장 세계의 유모세포 백혈병 시장, 최종사용자별(100만 달러)

• 세계의 유모세포 백혈병 시장 매출 점유율과 예측, 최종사용자별, 2023년-2033년
• 홈케어
• 병원
• 전문 클리닉
• 기타

제13장 세계의 유모세포 백혈병 시장 예측, 2019년-2033년(100만 달러)

제14장 세계의 유모세포 백혈병 시장, 치료 유형별, 2019년-2033년(100만 달러)

제15장 세계의 유모세포 백혈병 시장, 치료법별, 2019년-2033년(100만 달러)

제16장 세계의 유모세포 백혈병 시장, 제품 유형별, 2019년-2033년(100만 달러)

제17장 세계의 유모세포 백혈병 시장, 약제 클래스별, 2019년-2033년(100만 달러)

제18장 세계의 유모세포 백혈병 시장, 투여 경로별, 2019년-2033년(100만 달러)

제19장 세계의 유모세포 백혈병 시장, 최종사용자별, 2019년-2033년(100만 달러)

제20장 세계의 유모세포 백혈병 시장, 지역별, 2019년-2033년(100만 달러)

• 세계의 유모세포 백혈병 시장 규모와 지역별 시장 점유율(2019년-2026년)
• 세계의 유모세포 백혈병 시장 규모와 지역별 시장 점유율(2027년-2033년)
• 아시아태평양
• 유럽
• 중동 및 아프리카
• 북미
• 라틴아메리카

제21장 기업 개요

• AbbVie Inc
• Amgen Inc
• Astellas Pharma Inc
• Astex Therapeutics
• AstraZeneca
• Bayer AG
• Biogenomics Limited
• Bristol Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company Limited
• Dr. Reddy's Laboratories Ltd
• Eli Lilly and Company
• Emcure Pharmaceuticals
• Fresenius SE and Co. KGaA
• GlaxoSmithKline plc
• Hoffmann-La Roche
• Janssen Global Services
• Johnson & Johnson Services, Inc
• Merck & Co., Inc
• Novartis AG
• Pfizer Inc.
• Sumitomo Dainippon Pharma Co.
• Takeda Pharmaceutical Company Limited
• 기타

제22장 약어 리스트

제23장 참조 링크

제24장 결론

제25장 조사 범위

LSH

영문 목차

영문목차

Hairy Cell Leukemia Market Overview

According to SPER market research, 'Hairy Cell Leukemia Market Size- By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Hairy Cell Leukemia Market is predicted to reach USD 0.10 billion by 2033 with a CAGR of 4.89%.

Hairy cell leukaemia is a rare type of cancer, in which the bone marrow causes lymphocytes to develop out of control. The name "hairy cell leukaemia" refers to a characteristic of the disease's morphology. In hairy cell leukaemia, the extra B cells grow aberrant extensions and have a hairy appearance. The quantity of healthy white blood cells, red blood cells, and platelets in the body decrease noticeably as the number of leukaemia cells increases. Usually, the illness takes time to develop without any noticeable symptoms.

Healthcare services were affected as a result of the COVID-19 pandemic, reducing access to basic care, including diagnosis and treatment. Delays in the clinical trials for the new treatments have an impact on therapy developments. Disruptions in the supply chain made it difficult to manage treatment plans and obtain the necessary drugs. There were fewer in-person visits and monitoring sessions, which increased reliance on online consultations. Challenges with affordability and reimbursement arose as a result of financial issues.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2033

Base year considered 2022

Forecast period 2023-2033

Segments covered By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User

Regions covered Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America

Companies Covered AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Astex Therapeutics, AstraZeneca, Bayer AG, Biogenomics Limited, Bristol Myers Squibb Company, Fresenius SE and Co. KGaA, GlaxoSmithKline plc, Hoffmann-La Roche, Janssen Global Services,

Hairy Cell Leukemia Market Key Segments Covered

By Therapy Type: Based on the Therapy Type, Global Hairy Cell Leukemia Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy.

By Product Type: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Capsules, Parenterals, Tablets, Others.

By End User: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Homecare, Hospitals, Specialty Clinics, Others.

By Region: This research also includes data for Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Global Hairy Cell Leukemia Market

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Global Hairy Cell Leukemia Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Hairy Cell Leukemia Market

7. Global Hairy Cell Leukemia Market, By Treatment Type (USD Million)

• 7.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Treatment Type, 2023-2033
• 7.2. Medication
• 7.3. Surgery

8. Global Hairy Cell Leukemia Market, By Therapy Type (USD Million)

• 8.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Therapy Type, 2023-2033
• 8.2. Chemotherapy
• 8.3. Immunotherapy
• 8.4. Targeted Therapy

9. Global Hairy Cell Leukemia Market, By Product Type (USD Million)

• 9.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Product Type, 2023-2033
• 9.2. Capsules
• 9.3. Parenterals
• 9.4. Tablets
• 9.5. Others

10. Global Hairy Cell Leukemia Market, By Drug Class (USD Million)

• 10.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Drug Class, 2023-2033
• 10.2. Belzutifan
• 10.3. Bevacizumab
• 10.4. Carmustine
• 10.5. Everolimus
• 10.6. Lomustine
• 10.7. Temozolomide
• 10.8. Others

11. Global Hairy Cell Leukemia Market, By Route of Administration (USD Million)

• 11.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Route of Administration, 2023-2033
• 11.2. Oral
• 11.3. Parenteral
• 11.4. Others

12. Global Hairy Cell Leukemia Market, By End User (USD Million)

• 12.1. Global Hairy Cell Leukemia Market Value Share and Forecast, End User, 2023-2033
• 12.2. Homecare
• 12.3. Hospitals
• 12.4. Specialty Clinics
• 12.5. Others

13. Global Hairy Cell Leukemia Market Forecast, 2019-2033 (USD Million)

• 13.1. Global Hairy Cell Leukemia Market Size and Market Share

14. Global Hairy Cell Leukemia Market, By Treatment Type, 2019-2033 (USD Million)

• 14.1. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2019-2026)
• 14.2. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2027-2033)

15. Global Hairy Cell Leukemia Market, By Therapy Type, 2019-2033 (USD Million)

• 15.1. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2019-2026)
• 15.2. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2027-2033)

16. Global Hairy Cell Leukemia Market, By Product Type, 2019-2033 (USD Million)

• 16.1. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2019-2026)
• 16.2. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2027-2033)

17. Global Hairy Cell Leukemia Market, By Drug Class, 2019-2033 (USD Million)

• 17.1. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2019-2026)
• 17.2. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2027-2033)

18. Global Hairy Cell Leukemia Market, By Route of Administration, 2019-2033 (USD Million)

• 18.1. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2019-2026)
• 18.2. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2027-2033)

19. Global Hairy Cell Leukemia Market, By End User, 2019-2033 (USD Million)

• 19.1. Global Hairy Cell Leukemia Market Size and Market Share By End User (2019-2026)
• 19.2. Global Hairy Cell Leukemia Market Size and Market Share By End User (2027-2033)

20. Global Hairy Cell Leukemia Market, By Region, 2019-2033 (USD Million)

• 20.1. Global Hairy Cell Leukemia Market Size and Market Share By Region (2019-2026)
• 20.2. Global Hairy Cell Leukemia Market Size and Market Share By Region (2027-2033)
• 20.3. Asia-Pacific
  • 20.3.1. Australia
  • 20.3.2. China
  • 20.3.3. India
  • 20.3.4. Japan
  • 20.3.5. South Korea
  • 20.3.6. Rest of Asia-Pacific
• 20.4. Europe
  • 20.4.1. France
  • 20.4.2. Germany
  • 20.4.3. Italy
  • 20.4.4. Spain
  • 20.4.5. United Kingdom
  • 20.4.6. Rest of Europe
• 20.5. Middle East and Africa
  • 20.5.1. Kingdom of Saudi Arabia
  • 20.5.2. United Arab Emirates
  • 20.5.3. Rest of Middle East & Africa
• 20.6. North America
  • 20.6.1. Canada
  • 20.6.2. Mexico
  • 20.6.3. United States
• 20.7. Latin America
  • 20.7.1. Argentina
  • 20.7.2. Brazil
  • 20.7.3. Rest of Latin America

21. Company Profile

• 21.1. AbbVie Inc,
  • 21.1.1. Company details
  • 21.1.2. Financial outlook
  • 21.1.3. Product summary
  • 21.1.4. Recent developments
• 21.2. Amgen Inc
  • 21.2.1. Company details
  • 21.2.2. Financial outlook
  • 21.2.3. Product summary
  • 21.2.4. Recent developments
• 21.3. Astellas Pharma Inc
  • 21.3.1. Company details
  • 21.3.2. Financial outlook
  • 21.3.3. Product summary
  • 21.3.4. Recent developments
• 21.4. Astex Therapeutics
  • 21.4.1. Company details
  • 21.4.2. Financial outlook
  • 21.4.3. Product summary
  • 21.4.4. Recent developments
• 21.5. AstraZeneca
  • 21.5.1. Company details
  • 21.5.2. Financial outlook
  • 21.5.3. Product summary
  • 21.5.4. Recent developments
• 21.6. Bayer AG
  • 21.6.1. Company details
  • 21.6.2. Financial outlook
  • 21.6.3. Product summary
  • 21.6.4. Recent developments
• 21.7. Biogenomics Limited
  • 21.7.1. Company details
  • 21.7.2. Financial outlook
  • 21.7.3. Product summary
  • 21.7.4. Recent developments
• 21.8. Bristol Myers Squibb Company
  • 21.8.1. Company details
  • 21.8.2. Financial outlook
  • 21.8.3. Product summary
  • 21.8.4. Recent developments
• 21.9. Celgene Corporation
  • 21.9.1. Company details
  • 21.9.2. Financial outlook
  • 21.9.3. Product summary
  • 21.9.4. Recent developments
• 21.10. Daiichi Sankyo Company Limited
  • 21.10.1. Company details
  • 21.10.2. Financial outlook
  • 21.10.3. Product summary
  • 21.10.4. Recent developments
• 21.11. Dr. Reddy's Laboratories Ltd
  • 21.11.1. Company details
  • 21.11.2. Financial outlook
  • 21.11.3. Product summary
  • 21.11.4. Recent developments
• 21.12. Eli Lilly and Company
  • 21.12.1. Company details
  • 21.12.2. Financial outlook
  • 21.12.3. Product summary
  • 21.12.4. Recent developments
• 21.13. Emcure Pharmaceuticals
  • 21.13.1. Company details
  • 21.13.2. Financial outlook
  • 21.13.3. Product summary
  • 21.13.4. Recent developments
• 21.14. Fresenius SE and Co. KGaA
  • 21.14.1. Company details
  • 21.14.2. Financial outlook
  • 21.14.3. Product summary
  • 21.14.4. Recent developments
• 21.15. GlaxoSmithKline plc
  • 21.15.1. Company details
  • 21.15.2. Financial outlook
  • 21.15.3. Product summary
  • 21.15.4. Recent developments
• 21.16. Hoffmann-La Roche
  • 21.16.1. Company details
  • 21.16.2. Financial outlook
  • 21.16.3. Product summary
  • 21.16.4. Recent developments
• 21.17. Janssen Global Services
  • 21.17.1. Company details
  • 21.17.2. Financial outlook
  • 21.17.3. Product summary
  • 21.17.4. Recent developments
• 21.18. Johnson & Johnson Services, Inc.
  • 21.18.1. Company details
  • 21.18.2. Financial outlook
  • 21.18.3. Product summary
  • 21.18.4. Recent developments
• 21.19. Merck & Co., Inc
  • 21.19.1. Company details
  • 21.19.2. Financial outlook
  • 21.19.3. Product summary
  • 21.19.4. Recent developments
• 21.20. Novartis AG
  • 21.20.1. Company details
  • 21.20.2. Financial outlook
  • 21.20.3. Product summary
  • 21.20.4. Recent developments
• 21.21. Pfizer Inc.
  • 21.21.1. Company details
  • 21.21.2. Financial outlook
  • 21.21.3. Product summary
  • 21.21.4. Recent developments
• 21.22. Sumitomo Dainippon Pharma Co.,
  • 21.22.1. Company details
  • 21.22.2. Financial outlook
  • 21.22.3. Product summary
  • 21.22.4. Recent developments
• 21.23. Takeda Pharmaceutical Company Limited
  • 21.23.1. Company details
  • 21.23.2. Financial outlook
  • 21.23.3. Product summary
  • 21.23.4. Recent developments
• 21.24. Others

22. List of Abbreviations

23. Reference Links

24. Conclusion

25. Research Scope

관련자료